A5049044895- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Epigenetics and DNA Methylation
- Urological Disorders and Treatments
- Cancer-related molecular mechanisms research
- Urinary Bladder and Prostate Research
- Colorectal Cancer Screening and Detection
- Infectious Disease Case Reports and Treatments
- Esophageal Cancer Research and Treatment
- Urinary Tract Infections Management
- Mycobacterium research and diagnosis
- Ferroptosis and cancer prognosis
- Cytomegalovirus and herpesvirus research
- Prostate Cancer Diagnosis and Treatment
- Abdominal Trauma and Injuries
- Diet and metabolism studies
- Cancer Genomics and Diagnostics
- Pharmacological Effects of Natural Compounds
- Renal cell carcinoma treatment
- Amino Acid Enzymes and Metabolism
- Colorectal Cancer Surgical Treatments
- Abdominal Surgery and Complications
- Cancer Diagnosis and Treatment
- Appendicitis Diagnosis and Management
Erasmus MC
2019-2025
Erasmus MC Cancer Institute
2017-2024
Sint Franciscus Gasthuis
2024
Erasmus University Rotterdam
2018-2022
Ikazia Ziekenhuis
1999
Adjuvant intravesical instillations with bacillus Calmette-Guérin (BCG) is the recommended treatment option for patients intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC). Despite adequate BCG treatment, a large proportion of experience recurrence. Although radical cystectomy gold standard unresponsive NMIBC, some are unfit or unwilling to consider this option.To assess effectiveness Hyperthermic IntraVEsical Chemotherapy (HIVEC®) in NMIBC patients.A post-hoc analysis was...
Muscle-invasive bladder cancer (MIBC) is a heterogeneous disease, and gene expression profiling has identified several molecular subtypes with distinct biological clinicopathological characteristics. While MIBC subtyping primarily been based on messenger RNA (mRNA), long non-coding RNAs (lncRNAs) may provide additional resolution.
The recommended treatment for patients with Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) is radical cystectomy (RC). However, many refuse, or are unfit RC. Therefore, alternative bladder-sparing modalities needed BCG-unresponsive NMIBC. In this study we sought to assess the long-term efficacy of hyperthermic intravesical chemotherapy (HIVEC) as in patients.Retrospectively collected data from 56 NMIBC who received ≥5 HIVEC instillations between...
Neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) in patients with nonmetastatic muscle-invasive bladder cancer (MIBC) confers an absolute survival benefit of 5%-10%. There is evidence that molecular differences between tumors may impact response therapy, highlighting a need for clinically validated biomarkers predict NAC.Four cohorts were included. Inverse probability weighting was used make baseline characteristics (age, sex and clinical tumor stage) NAC-treated untreated...
Patients with muscle-invasive bladder cancer (MIBC) who receive radiotherapy curative intent are followed by imaging, cystoscopy, and urine cytology. However, interpretation of cytology cystoscopy is hampered the impact ionizing radiation on cells.
Aims Programmed death ligand 1 ( PD ‐L1) expression has predictive value for response to immune‐checkpoint inhibitor treatment in urothelial cancer patients. The consistency of ‐L1 among different specimen types, however, is unknown. aim this study compare matched transurethral resections the bladder TURB ), cystectomy specimens and lymph node metastases Methods results We performed SP 142) immunohistochemistry on whole tissue slides 115 carcinoma patients who had undergone , followed by...
Currently, markers are lacking that can identify patients with high risk nonmuscle invasive bladder cancer who will fail bacillus Calmette-Guérin treatment. Therefore, we evaluated the prognostic value of T1 substaging in primary cancer.Patients received ≥5 induction instillations were included. All tumors centrally reviewed, which included (microinvasion vs extensive invasion lamina propria). stratified into or highest subgroups according to major urology guidelines. Primary end point was...
Guidelines recommend neoadjuvant chemotherapy (NAC) for the treatment of nonmetastatic muscle-invasive bladder cancer (MIBC). NAC is, however, underutilized in practice because its associated limited overall survival (OS) benefit and significant treatment-related toxicity. We hypothesized that absence circulating tumour cells (CTCs) identifies MIBC patients with such a favourable prognosis may be withheld.The CirGuidance study was an open-label, multicentre trial included clinical stage...
No AccessJournal of UrologyAdult Urology1 Jul 2020A Urine Based Genomic Assay to Triage Patients with Hematuria for CystoscopyThis article is commented on by the following:Editorial CommentEditorial Comment Kim E. M. van Kessel, Joep J. de Jong, Angelique C. Ziel-van der Made, Hossain Roshani, Stefan Haensel, Josien H. Wolterbeek, Egbert R. Boevé, Eric G. Oomens, Niels Casteren, Manuel Krispin, Joost L. Boormans, Ewout W. Steyerberg, Wim Criekinge, and Ellen Zwarthoff KesselKim Kessel...
Microhematuria is a prevalent condition and the American Urological Association has developed new risk-stratified approach for evaluation of patients with microhematuria. Our objective was to provide first this important guideline.This multinational cohort study combines contemporary from 5 clinical trials 2 prospective registries who underwent urological hematuria. Patients were stratified into risk strata (low, intermediate or high risk) based on sex, age, degree hematuria, smoking...